Nivolumab (and other checkpoint inhibitors) work by activating T cells (the cells that are infected by HIV).
The mechanism seems to make sense! But we need to see via clinical trials that these drugs really work and for what classes of AIDS patients.
IIRC, I could be mistaken, but didn’t Trump Administration make it easier to bring new drugs to market faster?...................